The many faces of C/EBPδ and their relevance for inflammation and cancer

International Journal of Biological Sciences

Volumn 9, Issue 9, 2013, Pages 917-933

  Balamurugan, Kuppusamy ^a   Sterneck, Esta ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

C EBP; Cancer; Cell signaling; Inflammation; Transcription factor

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN DELTA; TRANSCRIPTION FACTOR;

ANIMAL; C/EBP; CANCER.; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SIGNALING; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; MOUSE; NEOPLASM; PHYSIOLOGY; RAT; REVIEW; SIGNAL TRANSDUCTION;

C/EBP; CANCER.; CELL SIGNALING; INFLAMMATION; TRANSCRIPTION FACTOR;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-DELTA; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; MICE; NEOPLASMS; RATS; SIGNAL TRANSDUCTION;

EID: 84884468052     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7224     Document Type: Review

References (178)

1. Ramji DP, Foka P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J. 2002; 365: 561-75. doi:10.1042/BJ20020508.
2. Tsukada J, Yoshida Y, Kominato Y, Auron PE. The CCAAT/enhancer (C/EBP) family of basic-leucine zipper (bZIP) transcription factors is a multifaceted highly-regulated system for gene regulation. Cytokine. 2011; 54: 6-19. doi:10.1016/j.cyto.2010.12.019.
3. Nerlov C. The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control. Trends Cell Biol. 2007; 17: 318-24. doi:10.1016/j.tcb.2007.07.004.
4. Sebastian T, Johnson PF. Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta. Cell Cycle. 2006; 5: 953-7.
5. Roos AB, Nord M. The emerging role of C/EBPs in glucocorticoid signaling: lessons from the lung. J Endocrinol. 2012; 212: 291-305. doi:10.1530/JOE-11-0369.
6. Takiguchi M. The C/EBP family of transcription factors in the liver and other organs. Int J Exp Pathol. 1998; 79: 369-91.
7. Cooper LA, Gutman DA, Chisolm C, Appin C, Kong J, Rong Y, et al. The tumor microenvironment strongly impacts master transcriptional regulators and gene expression class of glioblastoma. The American journal of pathology. 2012; 180: 2108-19. doi:10.1016/j.ajpath.2012.01.040.
8. Agrawal S, Hofmann WK, Tidow N, Ehrich M, van den Boom D, Koschmieder S, et al. The C/EBPdelta tumor suppressor is silenced by hypermethylation in acute myeloid leukemia. Blood. 2007; 109: 3895-905. doi:10.1182/blood-2006-08-040147.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74. doi:10.1016/j.cell.2011.02.013.
10. Egeblad M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18: 884-901. doi:10.1016/j.devcel.2010.05.012.
11. Tian M, Schiemann WP. The TGF-beta paradox in human cancer: an update. Future Oncol. 2009; 5: 259-71. doi:10.2217/14796694.5.2.259.
12. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003; 100: 8621-3. doi:10.1073/pnas.1633291100.
13. Grigoryan G, Reinke AW, Keating AE. Design of protein-interaction specificity gives selective bZIP-binding peptides. Nature. 2009; 458: 859-64. doi:10.1038/nature07885.
14. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. The Journal of clinical investigation. 2010; 120: 127-41. doi:10.1172/JCI40027.
15. Osada S, Yamamoto H, Nishihara T, Imagawa M. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem. 1996; 271: 3891-6.
16. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2001; 61: 2328-34.
17. Enwright JF, 3rd, Kawecki-Crook MA, Voss TC, Schaufele F, Day RN. A PIT-1 homeodomain mutant blocks the intranuclear recruitment of the CCAAT/enhancer binding protein alpha required for prolactin gene transcription. Mol Endocrinol. 2003; 17: 209-22.
18. Tong Y, Zhou J, Mizutani J, Fukuoka H, Ren SG, Gutierrez-Hartmann A, et al. CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Molecular endocrinology. 2011; 25: 1880-91. doi:10.1210/me.2011-1075.
19. Zhang Y, Liu T, Yan P, Huang T, Dewille J. Identification and characterization of CCAAT/enhancer binding protein delta (C/EBPdelta) target genes in G0 growth arrested mammary epithelial cells. BMC Mol Biol. 2008; 9: 83. doi:10.1186/1471-2199-9-83.
20. Borrelli S, Fanoni D, Dolfini D, Alotto D, Ravo M, Grober OM, et al. C/EBPdelta Gene Targets in Human Keratinocytes. PLoS One. 2010; 5: e13789. doi:10.1371/journal.pone.0013789.
21. Litvak V, Ramsey SA, Rust AG, Zak DE, Kennedy KA, Lampano AE, et al. Function of C/EBPdelta in a regulatory circuit that discriminates between transient and persistent TLR4-induced signals. Nat Immunol. 2009; 10: 437-43. doi:10.1038/ni.1721.
22. Kovacs KA, Steinmann M, Magistretti PJ, Halfon O, Cardinaux JR. CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation. J Biol Chem. 2003; 278: 36959-65. doi:10.1074/jbc.M303147200.
23. Wang JM, Ko CY, Chen LC, Wang WL, Chang WC. Functional role of NF-IL6beta and its sumoylation and acetylation modifications in promoter activation of cyclooxygenase 2 gene. Nucleic Acids Res. 2006; 34: 217-31. doi:10.1093/nar/gkj422.
24. Chamberlain W, Gonnella P, Alamdari N, Aversa Z, Hasselgren PO. Multiple muscle wasting-related transcription factors are acetylated in dexamethasone-treated muscle cells. Biochemistry and cell biology = Biochimie et biologie cellulaire. 2012; 90: 200-8. doi:10.1139/o11-082.
25. Chiang BT, Liu YW, Chen BK, Wang JM, Chang WC. Direct interaction of C/EBPdelta and Sp1 at the GC-enriched promoter region synergizes the IL-10 gene transcription in mouse macrophage. J Biomed Sci. 2006; 13: 621-35. doi:10.1007/s11373-006-9101-y.
26. Meruvu S, Hugendubler L, Mueller E. Regulation of adipocyte differentiation by the zinc finger protein ZNF638. The Journal of biological chemistry. 2011; 286: 26516-23. doi:10.1074/jbc.M110.212506.
27. Zhang J, Chang L, Chen C, Zhang M, Luo Y, Hamblin M, et al. Rad GTPase inhibits cardiac fibrosis through connective tissue growth factor. Cardiovasc Res. 2011; 91: 90-8. doi:10.1093/cvr/cvr068.
28. Bezy O, Elabd C, Cochet O, Petersen RK, Kristiansen K, Dani C, et al. Delta-interacting protein A, a new inhibitory partner of CCAAT/enhancer-binding protein beta, implicated in adipocyte differentiation. J Biol Chem. 2005; 280: 11432-8. doi:10.1074/jbc.M411741200.
29. Delany AM, Durant D, Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol. 2001; 15: 1781-9.
30. Okazaki K, Li J, Yu H, Fukui N, Sandell LJ. CCAAT/enhancer-binding proteins beta and delta mediate the repression of gene transcription of cartilage-derived retinoic acid-sensitive protein induced by interleukin-1 beta. J Biol Chem. 2002; 277: 31526-33. doi:10.1074/jbc.M202815200. M202815200 [pii].
31. Lacorte JM, Beigneux A, Parant M, Chambaz J. Repression of apoC-III gene expression by TNFalpha involves C/EBPdelta/NF-IL6beta via an IL-1 independent pathway. FEBS Lett. 1997; 415: 217-20.
32. Lacorte JM, Ktistaki E, Beigneux A, Zannis VI, Chambaz J, Talianidis I. Activation of CAAT enhancer-binding protein delta (C/EBPdelta) by interleukin-1 negatively influences apolipoprotein C-III expression. J Biol Chem. 1997; 272: 23578-84.
33. Qiu X, Aiken KJ, Chokas AL, Beachy DE, Nick HS. Distinct functions of CCAAT enhancer-binding protein isoforms in the regulation of manganese superoxide dismutase during interleukin-1beta stimulation. J Biol Chem. 2008; 283: 25774-85. doi:10.1074/jbc.M801178200.
34. Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R, et al. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 2010; 29: 4106-17. doi:emboj2010280 [pii] 10.1038/emboj.2010.280.
35. Turgeon N, Valiquette C, Blais M, Routhier S, Seidman EG, Asselin C. Regulation of C/EBPdelta-dependent transactivation by histone deacetylases in intestinal epithelial cells. J Cell Biochem. 2008; 103: 1573-83. doi:10.1002/jcb.21544.
36. Lai PH, Wang WL, Ko CY, Lee YC, Yang WM, Shen TW, et al. HDAC1/HDAC3 modulates PPARG2 transcription through the sumoylated CEBPD in hepatic lipogenesis. Biochim Biophys Acta. 2008; 1783: 1803-14. doi:S0167-4889(08)00225-5 [pii] 10.1016/j.bbamcr.2008.06.008.
37. Xu L, Panel V, Ma X, Du C, Hugendubler L, Gavrilova O, et al. The winged helix transcription factor foxa3 regulates adipocyte differentiation and depot-selective fat tissue expansion. Mol Cell Biol. 2013; 33: 3392-9. doi:10.1128/MCB.00244-13.
38. Turgeon N, Rousseau D, Roy E, Asselin C. GATA-4 modulates C/EBP-dependent transcriptional activation of acute phase protein genes. Biochem Biophys Res Commun. 2008; 370: 371-5. doi:S0006-291X(08)00603-7 [pii] 10.1016/j.bbrc.2008.03.107.
39. McCarthy TL, Ji CH, Chen Y, Kim KK, Imagawa M, Ito Y, et al. Runt domain factor (Runx)-dependent effects on CCAAT/enhancer-binding protein delta expression and activity in osteoblasts. Journal of Biological Chemistry. 2000; 275: 21746-53. doi:Doi 10.1074/Jbc.M002291200.
40. Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem. 2003; 278: 9609-19. doi:10.1074/jbc.M212259200.
41. Wang J, Roy Sarkar T, Zhou M, Sharan S, Ritt DA, Veenstra TD, et al. CCAAT/enhancer binding protein delta (C/EBP{delta}, CEBPD)-mediated nuclear import of FANCD2 by IPO4 augments cellular response to DNA damage. Proc Natl Acad Sci U S A. 2010; 107: 16131-6. doi:1002603107 [pii] 10.1073/pnas.1002603107.
42. Matsushita N, Endo Y, Sato K, Kurumizaka H, Yamashita T, Takata M, et al. Direct inhibition of TNF-alpha promoter activity by Fanconi anemia protein FANCD2. PLoS One. 2011; 6: e23324. doi:10.1371/journal.pone.0023324.
43. Park E, Kim H, Kim JM, Primack B, Vidal-Cardenas S, Xu Y, et al. FANCD2 activates transcription of TAp63 and suppresses tumorigenesis. Mol Cell. 2013; 50: 908-18. doi:10.1016/j.molcel.2013.05.017.
44. Tanaka T, Yoshida N, Kishimoto T, Akira S. Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. Embo J. 1997; 16: 7432-43. doi:10.1093/emboj/16.24.7432.
45. Sterneck E, Paylor R, Jackson-Lewis V, Libbey M, Przedborski S, Tessarollo L, et al. Selectively enhanced contextual fear conditioning in mice lacking the transcriptional regulator CCAAT/enhancer binding protein delta. Proc Natl Acad Sci U S A. 1998; 95: 10908-13.
46. Takiguchi M, Mori M. In vitro analysis of the rat liver-type arginase promoter. J Biol Chem. 1991; 266: 9186-93.
47. Tang Y, Pacary E, Freret T, Divoux D, Petit E, Schumann-Bard P, et al. Effect of hypoxic preconditioning on brain genomic response before and following ischemia in the adult mouse: identification of potential neuroprotective candidates for stroke. Neurobiol Dis. 2006; 21: 18-28. doi:10.1016/j.nbd.2005.06.002.
48. Min Y, Ghose S, Boelte K, Li J, Yang L, Lin PC. C/EBP-delta regulates VEGF-C autocrine signaling in lymphangiogenesis and metastasis of lung cancer through HIF-1alpha. Oncogene. 2011; 30: 4901-9. doi:10.1038/onc.2011.187.
49. Wotton S, Terry A, Kilbey A, Jenkins A, Herzyk P, Cameron E, et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene. 2008; 27: 5856-66. doi:onc2008195 [pii] 10.1038/onc.2008.195.
50. Glaros T, Fu Y, Xing J, Li L. Molecular mechanism underlying persistent induction of LCN2 by lipopolysaccharide in kidney fibroblasts. PLoS One. 2012; 7: e34633. doi:10.1371/journal.pone.0034633.
51. Liu YW, Wang SA, Hsu TY, Chen TA, Chang WC, Hung JJ. Inhibition of LPS-induced C/EBP delta by trichostatin A has a positive effect on LPS-induced cyclooxygenase 2 expression in RAW264.7 cells. J Cell Biochem. 2010; 110: 1430-8. doi:10.1002/jcb.22682.
52. Borrelli S, Testoni B, Callari M, Alotto D, Castagnoli C, Romano RA, et al. Reciprocal regulation of p63 by C/EBP delta in human keratinocytes. BMC Mol Biol. 2007; 8: 85. doi:10.1186/1471-2199-8-85.
53. Li B, Si J, DeWille JW. Ultraviolet radiation (UVR) activates p38 MAP kinase and induces post-transcriptional stabilization of the C/EBPdelta mRNA in G0 growth arrested mammary epithelial cells. J Cell Biochem. 2008; 103: 1657-69. doi:10.1002/jcb.21554.
54. Hsiao YW, Li CF, Chi JY, Tseng JT, Chang Y, Hsu LJ, et al. CCAAT/Enhancer Binding Protein delta in Macrophages Contributes to Immunosuppression and Inhibits Phagocytosis in Nasopharyngeal Carcinoma. Sci Signal. 2013; 6: ra59. doi:10.1126/scisignal.2003648.
55. Banerjee S, Xie N, Cui H, Tan Z, Yang S, Icyuz M, et al. MicroRNA let-7c regulates macrophage polarization. J Immunol. 2013; 190: 6542-9. doi:10.4049/jimmunol.1202496.
56. Sarkar TR, Sharan S, Wang J, Pawar SA, Cantwell CA, Johnson PF, et al. Identification of a Src tyrosine kinase/SIAH2 E3 ubiquitin ligase pathway that regulates C/EBPdelta expression and contributes to transformation of breast tumor cells. Mol Cell Biol. 2012; 32: 320-32. doi:10.1128/mcb.05790-11.
57. Balamurugan K, Sharan S, Klarmann KD, Zhang Y, Coppola V, Summers GH, et al. FBXW7alpha attenuates inflammatory signalling by downregulating C/EBPdelta and its target gene Tlr4. Nature communications. 2013; 4: 1662. doi:10.1038/ncomms2677.
58. House CM, Moller A, Bowtell DD. Siah proteins: novel drug targets in the Ras and hypoxia pathways. Cancer Res. 2009; 69: 8835-8. doi:10.1158/0008-5472.can-09-1676.
59. Cheng Y, Li G. Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metastasis Rev. 2012; 31: 75-87. doi:10.1007/s10555-011-9330-z.
60. Ji C, Chang W, Centrella M, McCarthy TL. Activation domains of CCAAT enhancer binding protein delta: regions required for native activity and prostaglandin E2-dependent transactivation of insulin-like growth factor I gene expression in rat osteoblasts. Mol Endocrinol. 2003; 17: 1834-43. doi:10.1210/me.2002-0235.
61. Kravchenko VV, Mathison JC, Schwamborn K, Mercurio F, Ulevitch RJ. IKKi/IKKepsilon plays a key role in integrating signals induced by pro-inflammatory stimuli. J Biol Chem. 2003; 278: 26612-9. doi:10.1074/jbc.M303001200.
62. Ray A, Ray BK. Serum amyloid A gene expression under acute-phase conditions involves participation of inducible C/EBP-beta and C/EBP-delta and their activation by phosphorylation. Mol Cell Biol. 1994; 14: 4324-32.
63. Yin M, Yang SQ, Lin HZ, Lane MD, Chatterjee S, Diehl AM. Tumor necrosis factor alpha promotes nuclear localization of cytokine-inducible CCAAT/enhancer binding protein isoforms in hepatocytes. J Biol Chem. 1996; 271: 17974-8.
64. Billiard J, Umayahara Y, Wiren K, Centrella M, McCarthy TL, Rotwein P. Regulated nuclear-cytoplasmic localization of CCAAT/enhancer-binding protein delta in osteoblasts. J Biol Chem. 2001; 276: 15354-61. doi:10.1074/jbc.M009973200.
65. Kitami Y, Fukuoka T, Hiwada K, Inagami T. A high level of CCAAT-enhancer binding protein-delta expression is a major determinant for markedly elevated differential gene expression of the platelet-derived growth factor-alpha receptor in vascular smooth muscle cells of genetically hypertensive rats. Circ Res. 1999; 84: 64-73.
66. Fukuoka T, Kitami Y, Okura T, Hiwada K. Transcriptional regulation of the platelet-derived growth factor alpha receptor gene via CCAAT/enhancer-binding protein-delta in vascular smooth muscle cells. J Biol Chem. 1999; 274: 25576-82.
67. Zhou S, Si J, Liu T, DeWille JW. PIASy represses CCAAT/enhancer-binding protein delta (C/EBPdelta) transcriptional activity by sequestering C/EBPdelta to the nuclear periphery. J Biol Chem. 2008; 283: 20137-48. doi:10.1074/jbc.M801307200.
68. Tang QQ, Lane MD. Activation and centromeric localization of CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte differentiation. Genes Dev. 1999; 13: 2231-41.
69. Billiard J, Grewal SS, Lukaesko L, Stork PJ, Rotwein P. Hormonal control of insulin-like growth factor I gene transcription in human osteoblasts: dual actions of cAMP-dependent protein kinase on CCAAT/enhancer-binding protein delta. J Biol Chem. 2001; 276: 31238-46. doi:10.1074/jbc.M103634200.
70. Thangaraju M, Rudelius M, Bierie B, Raffeld M, Sharan S, Hennighausen L, et al. C/EBPdelta is a crucial regulator of pro-apoptotic gene expression during mammary gland involution. Development. 2005; 132: 4675-85. doi:10.1242/dev.02050.
71. Huang AM, Rudelius M, Sharan S, McAllister JM, Raffeld M, Christenson LK, et al. The Cebpd (C/EBPdelta) gene is induced by luteinizing hormones in ovarian theca and interstitial cells but is not essential for mouse ovary function. PLoS One. 2007; 2: e1334. doi:10.1371/journal.pone.0001334.
72. Milde-Langosch K, Loning T, Bamberger AM. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins. Breast Cancer Res Treat. 2003; 79: 175-85.
73. Barresi V, Vitarelli E, Cerasoli S, Barresi G. The cell growth inhibitory transcription factor C/EBPdelta is expressed in human meningiomas in association with low histological grade and proliferation index. J Neurooncol. 2010; 97: 233-40. doi:10.1007/s11060-009-0024-0.
74. Sugahara K, Sadohara T, Sugita M, Iyama K, Takiguchi M. Differential expression of CCAAT enhancer binding protein family in rat alveolar epithelial cell proliferation and in acute lung injury. Cell Tissue Res. 1999; 297: 261-70.
75. Duitman J, Hoogendijk AJ, Groot AP, Ruela de Sousa RR, van der Poll T, Florquin S, et al. CCAAT-enhancer binding protein delta (C/EBPdelta) protects against Klebsiella pneumoniae-induced pulmonary infection: potential role for macrophage migration. The Journal of infectious diseases. 2012; 206: 1826-35. doi:10.1093/infdis/jis615.
76. Johnson PF. Molecular stop signs: regulation of cell-cycle arrest by C/EBP transcription factors. Journal of cell science. 2005; 118: 2545-55. doi:10.1242/jcs.02459.
77. Jones LC, Lin ML, Chen SS, Krug U, Hofmann WK, Lee S, et al. Expression of C/EBPbeta from the C/ebpalpha gene locus is sufficient for normal hematopoiesis in vivo. Blood. 2002; 99: 2032-6.
78. Chiu CH, Lin WD, Huang SY, Lee YH. Effect of a C/EBP gene replacement on mitochondrial biogenesis in fat cells. Genes Dev. 2004; 18: 1970-5. doi:10.1101/gad.1213104.
79. Yan C, Zhu M, Staiger J, Johnson PF, Gao H. C5a-regulated CCAAT/enhancer binding protein beta and-delta are essential in Fcgamma receptor-mediated inflammatory cytokine and chemokine production in macrophages. J Biol Chem. 2012; 287: 3217-30. doi:10.1074/jbc.M111.280834.
80. Lu YC, Kim I, Lye E, Shen F, Suzuki N, Suzuki S, et al. Differential role for c-Rel and C/EBPbeta/delta in TLR-mediated induction of proinflammatory cytokines. J Immunol. 2009; 182: 7212-21. doi:10.4049/jimmunol.0802971.
81. Staiger J, Lueben MJ, Berrigan D, Malik R, Perkins SN, Hursting SD, et al. C/EBPbeta regulates body composition, energy balance-related hormones and tumor growth. Carcinogenesis. 2009; 30: 832-40. doi:10.1093/carcin/bgn273.
82. Yan C, Johnson PF, Tang H, Ye Y, Wu M, Gao H. CCAAT/Enhancer-Binding Protein delta Is a Critical Mediator of Lipopolysaccharide-Induced Acute Lung Injury. The American journal of pathology. 2012. doi:10.1016/j.ajpath.2012.10.013.
83. Yan C, Wu M, Cao J, Tang H, Zhu M, Johnson PF, et al. Critical role for CCAAT/enhancer-binding protein beta in immune complex-induced acute lung injury. J Immunol. 2012; 189: 1480-90. doi:10.4049/jimmunol.1200877.
84. Yang L, Jiang Y, Wu SF, Zhou MY, Wu YL, Chen GQ. CCAAT/enhancer-binding protein alpha antagonizes transcriptional activity of hypoxia-inducible factor 1 alpha with direct protein-protein interaction. Carcinogenesis. 2008; 29: 291-8. doi:10.1093/carcin/bgm262.
85. O'Rourke JP, Newbound GC, Hutt JA, DeWille J. CCAAT/enhancer-binding protein delta regulates mammary epithelial cell G0 growth arrest and apoptosis. J Biol Chem. 1999; 274: 16582-9.
86. Dearth LR, DeWille J. Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells. J Biol Chem. 2003; 278: 11246-55. doi:10.1074/jbc.M207930200.
87. Huang AM, Montagna C, Sharan S, Ni Y, Ried T, Sterneck E. Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability. Oncogene. 2004; 23: 1549-57. doi:10.1038/sj.onc.1207285.
88. Hutt JA, DeWille JW. Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway. Mol Cancer Ther. 2002; 1: 601-10.
89. Pawar SA, Roy Sarkar T, Balamurugan K, Sharan S, Wang J, Zhang Y, et al. C/EBP{delta} targets cyclin D1 for proteasome-mediated degradation via induction of CDC27/APC3 expression. Proc Natl Acad Sci U S A. 2010; 107: 9210-5. doi:0913813107 [pii] 10.1073/pnas.0913813107.
90. Gigliotti AP, Johnson PF, Sterneck E, DeWille JW. Nulliparous CCAAT/enhancer binding proteindelta (C/EBPdelta) knockout mice exhibit mammary gland ductal hyperlasia. Exp Biol Med (Maywood). 2003; 228: 278-85.
91. Gery S, Tanosaki S, Hofmann WK, Koppel A, Koeffler HP. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. Oncogene. 2005; 24: 1589-97. doi:1208393 [pii] 10.1038/sj.onc.1208393.
92. Sanford DC, DeWille JW. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate. 2005; 63: 143-54. doi:10.1002/pros.20159.
93. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, et al. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res. 2005; 65: 4762-8. doi:10.1158/0008-5472.CAN-03-3619.
94. Yang G, Gregory CW, Shang Q, O'Brien DA, Zhang YL. Differential expression of CCAAT/enhancer-binding protein-delta (c/EBPdelta) in rat androgen-dependent tissues and human prostate cancer. J Androl. 2001; 22: 471-80.
95. Umayahara Y, Ji C, Centrella M, Rotwein P, McCarthy TL. CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone. J Biol Chem. 1997; 272: 31793-800.
96. Hishida T, Nishizuka M, Osada S, Imagawa M. The role of C/EBPdelta in the early stages of adipogenesis. Biochimie. 2009; 91: 654-7. doi:10.1016/j.biochi.2009.02.002.
97. Siersbaek R, Nielsen R, John S, Sung MH, Baek S, Loft A, et al. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. Embo J. 2011; 30: 1459-72. doi:10.1038/emboj.2011.65.
98. Chen PL, Riley DJ, Chen YM, Lee WH. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes & Development. 1996; 10: 2794-804. doi:Doi 10.1101/Gad.10.21.2794.
99. Pan YC, Li CF, Ko CY, Pan MH, Chen PJ, Tseng JT, et al. CEBPD reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells. Clin Cancer Res. 2010; 16: 5770-80. doi:10.1158/1078-0432.CCR-10-1025.
100. Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006; 103: 2794-9. doi:10.1073/pnas.0510423103.
101. Wang QF, Friedman AD. CCAAT/enhancer-binding proteins are required for granulopoiesis independent of their induction of the granulocyte colony-stimulating factor receptor. Blood. 2002; 99: 2776-85.
102. Scott LM, Civin CI, Rorth P, Friedman AD. A novel temporal expression pattern of three C/EBP family members in differentiating myelomonocytic cells. Blood. 1992; 80: 1725-35.
103. Barbaro V, Testa A, Di Iorio E, Mavilio F, Pellegrini G, De Luca M. C/EBPdelta regulates cell cycle and self-renewal of human limbal stem cells. J Cell Biol. 2007; 177: 1037-49. doi:jcb.200703003 [pii] 10.1083/jcb.200703003.
104. Wright LS, Li J, Caldwell MA, Wallace K, Johnson JA, Svendsen CN. Gene expression in human neural stem cells: effects of leukemia inhibitory factor. Journal of neurochemistry. 2003; 86: 179-95.
105. Buckley SM, Aranda-Orgilles B, Strikoudis A, Apostolou E, Loizou E, Moran-Crusio K, et al. Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell. 2012; 11: 783-98. doi:10.1016/j.stem.2012.09.011.
106. Wang Z, Inuzuka H, Fukushima H, Wan L, Gao D, Shaik S, et al. Emerging roles of the FBW7 tumour suppressor in stem cell differentiation. EMBO Rep. 2012; 13: 36-43. doi:10.1038/embor.2011.231.
107. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer cell. 2013; 23: 347-61. doi:10.1016/j.ccr.2013.01.026.
108. Porter DA, Krop IE, Nasser S, Sgroi D, Kaelin CM, Marks JR, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. Cancer Res. 2001; 61: 5697-702.
109. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, et al. Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev. 1999; 13: 2604-16.
110. Resemann HK, Watson CJ, Lloyd-Lewis B. The Stat3 paradox: A killer and an oncogene. Molecular and cellular endocrinology. 2013. doi:10.1016/j.mce.2013.06.029.
111. Ranger JJ, Levy DE, Shahalizadeh S, Hallett M, Muller WJ. Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. Cancer Res. 2009; 69: 6823-30. doi:10.1158/0008-5472.CAN-09-1684.
112. Moore F, Santin I, Nogueira TC, Gurzov EN, Marselli L, Marchetti P, et al. The transcription factor C/EBP delta has anti-apoptotic and anti-inflammatory roles in pancreatic beta cells. PLoS One. 2012; 7: e31062. doi:10.1371/journal.pone.0031062.
113. Hour TC, Lai YL, Kuan CI, Chou CK, Wang JM, Tu HY, et al. Transcriptional up-regulation of SOD1 by CEBPD: A potential target for cisplatin resistant human urothelial carcinoma cells. Biochem Pharmacol. 2010; 80: 325-34. doi:S0006-2952(10)00252-2 [pii] 10.1016/j.bcp.2010.04.007.
114. Wu SR, Li CF, Hung LY, Huang AM, Tseng JT, Tsou JH, et al. CCAAT/enhancer-binding protein delta mediates tumor necrosis factor alpha-induced Aurora kinase C transcription and promotes genomic instability. J Biol Chem. 2011; 286: 28662-70. doi:10.1074/jbc.M111.270710.
115. Huber R, Pietsch D, Panterodt T, Brand K. Regulation of C/EBPbeta and resulting functions in cells of the monocytic lineage. Cellular signalling. 2012; 24: 1287-96. doi:10.1016/j.cellsig.2012.02.007.
116. Akagi T, Thoennissen NH, George A, Crooks G, Song JH, Okamoto R, et al. In vivo deficiency of both C/EBPbeta and C/EBPepsilon results in highly defective myeloid differentiation and lack of cytokine response. PLoS One. 2010; 5: e15419. doi:10.1371/journal.pone.0015419.
117. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011; 34: 637-50. doi:10.1016/j.immuni.2011.05.006.
118. Maitra U, Gan L, Chang S, Li L. Low-Dose Endotoxin Induces Inflammation by Selectively Removing Nuclear Receptors and Activating CCAAT/Enhancer-Binding Protein {delta}. J Immunol. 2011; 186: 4467-73. doi:10.4049/jimmunol.1003300.
119. Yan C, Ward PA, Wang X, Gao H. Myeloid depletion of SOCS3 enhances LPS-induced acute lung injury through CCAAT/enhancer binding protein delta pathway. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2013; 27: 2967-76. doi:10.1096/fj.12-225797.
120. Duitman J, Schouten M, Groot AP, Daalhuisen JB, Florquin S, van der Poll T, et al. CCAAT/enhancer-binding protein delta facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner. Proc Natl Acad Sci U S A. 2012; 109: 9113-8. doi:10.1073/pnas.1202641109.
121. Goldszmid RS, Trinchieri G. The price of immunity. Nat Immunol. 2012; 13: 932-8. doi:10.1038/ni.2422.
122. Slofstra SH, Groot AP, Obdeijn MH, Reitsma PH, ten Cate H, Spek CA. Gene expression profiling identifies C/EBPdelta as a candidate regulator of endotoxin-induced disseminated intravascular coagulation. Am J Respir Crit Care Med. 2007; 176: 602-9. doi:10.1164/rccm.200609-1250OC.
123. Poli V. The role of C/EBP isoforms in the control of inflammatory and native immunity functions. J Biol Chem. 1998; 273: 29279-82.
124. Li R, Strohmeyer R, Liang Z, Lue LF, Rogers J. CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. Neurobiology of aging. 2004; 25: 991-9. doi:10.1016/j.neurobiolaging.2003.10.016.
125. Ko CY, Chang LH, Lee YC, Sterneck E, Cheng CP, Chen SH, et al. CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells. Neurobiology of aging. 2012; 33: 422. e11-25. doi:10.1016/j.neurobiolaging.2010.09.017.
126. Tsai VW, Mohammad MG, Tolhurst O, Breit SN, Sawchenko PE, Brown DA. CCAAT/enhancer binding protein-delta expression by dendritic cells regulates CNS autoimmune inflammatory disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2011; 31: 17612-21. doi:10.1523/JNEUROSCI.3449-11.2011.
127. Valente T, Straccia M, Gresa-Arribas N, Dentesano G, Tusell JM, Serratosa J, et al. CCAAT/enhancer binding protein delta regulates glial proinflammatory gene expression. Neurobiology of aging. 2013; 34: 2110-24. doi:10.1016/j.neurobiolaging.2013.02.007.
128. Gresa-Arribas N, Serratosa J, Saura J, Sola C. Inhibition of CCAAT/enhancer binding protein delta expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects. Journal of neurochemistry. 2010; 115: 526-36. doi:10.1111/j.1471-4159.2010.06952.x.
129. Chang LH, Huang HS, Wu PT, Jou IM, Pan MH, Chang WC, et al. Role of macrophage CCAAT/enhancer binding protein delta in the pathogenesis of rheumatoid arthritis in collagen-induced arthritic mice. PLoS One. 2012; 7: e45378. doi:10.1371/journal.pone.0045378.
130. Massaad C, Paradon M, Jacques C, Salvat C, Bereziat G, Berenbaum F, et al. Induction of secreted type IIA phospholipase A2 gene transcription by interleukin-1beta. Role of C/EBP factors. J Biol Chem. 2000; 275: 22686-94. doi:10.1074/jbc.M001250200.
131. Sai S, Esteves CL, Kelly V, Michailidou Z, Anderson K, Coll AP, et al. Glucocorticoid regulation of the promoter of 11beta-hydroxysteroid dehydrogenase type 1 is indirect and requires CCAAT/enhancer-binding protein-beta. Mol Endocrinol. 2008; 22: 2049-60. doi:10.1210/me.2007-0489.
132. Allen DL, Cleary AS, Hanson AM, Lindsay SF, Reed JM. CCAAT/enhancer binding protein-delta expression is increased in fast skeletal muscle by food deprivation and regulates myostatin transcription in vitro. American journal of physiology Regulatory, integrative and comparative physiology. 2010; 299: R1592-601. doi:10.1152/ajpregu.00247.2010.
133. Liu YW, Tseng HP, Chen LC, Chen BK, Chang WC. Functional cooperation of simian virus 40 promoter factor 1 and CCAAT/enhancer-binding protein beta and delta in lipopolysaccharide-induced gene activation of IL-10 in mouse macrophages. J Immunol. 2003; 171: 821-8.
134. Si J, Yu X, Zhang Y, DeWille JW. Myc interacts with Max and Miz1 to repress C/EBPdelta promoter activity and gene expression. Mol Cancer. 2010; 9: 92. doi:10.1186/1476-4598-9-92.
135. Do-Umehara HC, Chen C, Urich D, Zhou L, Qiu J, Jang S, et al. Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-delta. Nat Immunol. 2013; 14: 461-9. doi:10.1038/ni.2566.
136. Takata Y, Kitami Y, Yang ZH, Nakamura M, Okura T, Hiwada K. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res. 2002; 91: 427-33.
137. Kaundal RK, Sharma SS. Peroxisome proliferator-activated receptor gamma agonists as neuroprotective agents. Drug news & perspectives. 2010; 23: 241-56. doi:10.1358/dnp.2010.23.4.1437710.
138. Klamer G, Song E, Ko KH, O'Brien TA, Dolnikov A. Using small molecule GSK3beta inhibitors to treat inflammation. Current medicinal chemistry. 2010; 17: 2873-81.
139. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003; 1: 362-75.
140. Zucchi I, Mento E, Kuznetsov VA, Scotti M, Valsecchi V, Simionati B, et al. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Natl Acad Sci U S A. 2004; 101: 18147-52. doi:10.1073/pnas.0408260101.
141. Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, et al. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2007; 26: 1507-16. doi:10.1038/sj.onc.1209920.
142. Ko CY, Hsu HC, Shen MR, Chang WC, Wang JM. Epigenetic silencing of CCAAT/enhancer-binding protein delta activity by YY1/polycomb group/DNA methyltransferase complex. J Biol Chem. 2008; 283: 30919-32. doi:10.1074/jbc.M804029200.
143. Tang D, Sivko GS, DeWille JW. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors. Breast Cancer Res Treat. 2005; 95: 161-70. doi:10.1007/s10549-005-9061-3.
144. Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, et al. Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPdelta) CpG island in breast cancer is associated with metastatic relapse. Br J Cancer. 2012; 107: 732-8. doi:10.1038/bjc.2012.308.
145. Ceccarelli V, Racanicchi S, Martelli MP, Nocentini G, Fettucciari K, Riccardi C, et al. Eicosapentaenoic acid demethylates a single CpG that mediates expression of tumor suppressor CCAAT/enhancer-binding protein delta in U937 leukemia cells. J Biol Chem. 2011; 286: 27092-102. doi:10.1074/jbc.M111.253609.
146. Brueckner LM, Hess EM, Schwab M, Savelyeva L. Instability at the FRA8I common fragile site disrupts the genomic integrity of the KIAA0146, CEBPD and PRKDC genes in colorectal cancer. Cancer Lett. 2013; 336: 85-95. doi:10.1016/j.canlet.2013.04.007.
147. Tang D, DeWille J. Detection of base sequence changes in the CEBPD gene in human breast cancer cell lines and primary breast cancer isolates. Mol Cell Probes. 2003; 17: 11-4.
148. Vegesna V, Takeuchi S, Hofmann WK, Ikezoe T, Tavor S, Krug U, et al. C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies. Leuk Res. 2002; 26: 451-7.
149. Bennett CE, Nsengimana J, Bostock JA, Cymbalista C, Futers TS, Knight BL, et al. CCAAT/enhancer binding protein alpha, beta and delta gene variants: associations with obesity related phenotypes in the Leeds Family Study. Diab Vasc Dis Res. 2010; 7: 195-203. doi:10.1177/1479164110366274.
150. Angeloni D, Lee JD, Johnson BE, Teh BT, Dean M, Lerman MI, et al. C306A single nucleotide polymorphism in the human CEBPD gene that maps at 8p11.1-p11.2. Molecular and Cellular Probes. 2001; 15: 395-7. doi:Doi 10.1006/Mcpr.2001.0377.
151. Tong Y, Zheng Y, Zhou J, Oyesiku NM, Koeffler HP, Melmed S. Genomic characterization of human and rat prolactinomas. Endocrinology. 2012; 153: 3679-91. doi:10.1210/en.2012-1056.
152. Covell DG, Wallqvist A, Rabow AA, Thanki N. Molecular classification of cancer: unsupervised self-organizing map analysis of gene expression microarray data. Mol Cancer Ther. 2003; 2: 317-32.
153. Willenbrock K, Kuppers R, Renne C, Brune V, Eckerle S, Weidmann E, et al. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica. 2006; 91: 596-604.
154. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature. 2010; 463: 318-25. doi:10.1038/nature08712.
155. Hagedorn M, Delugin M, Abraldes I, Allain N, Belaud-Rotureau MA, Turmo M, et al. FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div. 2007; 2: 9. doi:10.1186/1747-1028-2-9.
156. Shay JE, Celeste Simon M. Hypoxia-inducible factors: crosstalk between inflammation and metabolism. Seminars in cell & developmental biology. 2012; 23: 389-94. doi:10.1016/j.semcdb.2012.04.004.
157. Trinchieri G. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annual review of immunology. 2012; 30: 677-706. doi:10.1146/annurev-immunol-020711-075008.
158. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends in pharmacological sciences. 2012; 33: 207-14. doi:10.1016/j.tips.2012.01.005.
159. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-32. doi:10.1038/nrc1187.
160. Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004; 57: 1009-14. doi:10.1136/jcp.2003.015032.
161. Bosco MC, Puppo M, Blengio F, Fraone T, Cappello P, Giovarelli M, et al. Monocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration. Immunobiology. 2008; 213: 733-49. doi:10.1016/j.imbio.2008.07.031.
162. Feinberg MW, Watanabe M, Lebedeva MA, Depina AS, Hanai J, Mammoto T, et al. Transforming growth factor-beta1 inhibition of vascular smooth muscle cell activation is mediated via Smad3. J Biol Chem. 2004; 279: 16388-93. doi:10.1074/jbc.M309664200.
163. de Heredia LL, Magoulas C. Lack of the transcription factor C/EBPdelta impairs the intrinsic capacity of peripheral neurons for regeneration. Exp Neurol. 2012. doi:10.1016/j.expneurol.2012.10.012.
164. Chang LH, Huang HS, Wu PT, Jou IM, Pan MH, Chang WC, et al. Role of Macrophage CCAAT/Enhancer Binding Protein Delta in the Pathogenesis of Rheumatoid Arthritis in Collagen-Induced Arthritic Mice. PLoS ONE 2012; 7:e45378.
165. Thangaraju M, Ananth S, Martin PM, Roon P, Smith SB, Sterneck E, et al. c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J Biol Chem. 2006; 281: 26769-73. doi:C600189200 [pii] 10.1074/jbc.C600189200.
166. Takeji M, Kawada N, Moriyama T, Nagatoya K, Oseto S, Akira S, et al. CCAAT/Enhancer-binding protein delta contributes to myofibroblast transdifferentiation and renal disease progression. J Am Soc Nephrol. 2004; 15: 2383-90. doi:10.1097/01.ASN.0000136426.01160.2F.
167. Wang JM, Tseng JT, Chang WC. Induction of human NF-IL6beta by epidermal growth factor is mediated through the p38 signaling pathway and cAMP response element-binding protein activation in A431 cells. Mol Biol Cell. 2005; 16: 3365-76. doi:10.1091/mbc.E05-02-0105.
168. Chen H, Libertini SJ, George M, Dandekar S, Tepper CG, Al-Bataina B, et al. Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines. Endocrine-related cancer. 2010; 17: 857-73. doi:10.1677/ERC-10-0081.
169. Khan JA, Bellance C, Guiochon-Mantel A, Lombes M, Loosfelt H. Differential regulation of breast cancer-associated genes by progesterone receptor isoforms PRA and PRB in a new bi-inducible breast cancer cell line. PLoS One. 2012; 7: e45993. doi:10.1371/journal.pone.0045993.
170. Ali S, Singh NN, Yildirim H, Ramji DP. Requirement for nuclear factor kappa B signalling in the interleukin-1-induced expression of the CCAAT/enhancer binding protein-delta gene in hepatocytes. The international journal of biochemistry & cell biology. 2010; 42: 113-9. doi:10.1016/j.biocel.2009.09.018.
171. Cantwell CA, Sterneck E, Johnson PF. Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1. Mol Cell Biol. 1998; 18: 2108-17.
172. Sekine O, Nishio Y, Egawa K, Nakamura T, Maegawa H, Kashiwagi A. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J Biol Chem. 2002; 277: 36631-9. doi:10.1074/jbc.M206266200.
173. Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, et al. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell death and differentiation. 2012; 19: 1381-9. doi:10.1038/cdd.2012.15.
174. Cardinaux JR, Magistretti PJ. Vasoactive intestinal peptide, pituitary adenylate cyclase-activating peptide, and noradrenaline induce the transcription factors CCAAT/enhancer binding protein (C/EBP)-beta and C/EBP delta in mouse cortical astrocytes: involvement in cAMP-regulated glycogen metabolism. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1996; 16: 919-29.
175. Borges TJ, Lopes RL, Pinho NG, Machado FD, Souza AP, Bonorino C. Extracellular Hsp70 inhibits pro-inflammatory cytokine production by IL-10 driven down-regulation of C/EBPbeta and C/EBPdelta. Int J Hyperthermia. 2013; 29: 455-63. doi:10.3109/02656736.2013.798037.
176. Wang Y, Sul HS. Pref-1 regulates mesenchymal cell commitment and differentiation through Sox9. Cell metabolism. 2009; 9: 287-302. doi:10.1016/j.cmet.2009.01.013.
177. Zhang K, Wang S, Malhotra J, Hassler JR, Back SH, Wang G, et al. The unfolded protein response transducer IRE1alpha prevents ER stress-induced hepatic steatosis. Embo J. 2011; 30: 1357-75. doi:10.1038/emboj.2011.52.
178. Svotelis A, Doyon G, Bernatchez G, Desilets A, Rivard N, Asselin C. IL-1 beta-dependent regulation of C/EBP delta transcriptional activity. Biochem Biophys Res Commun. 2005; 328: 461-70. doi:10.1016/j.bbrc.2005.01.002.